A Novel Uremic Score Reflecting Accumulation of Specific Uremic Toxins More Precisely Predicts One-Year Mortality after Hemodialysis Commencement: A Retrospective Cohort Study.


Journal

Toxins
ISSN: 2072-6651
Titre abrégé: Toxins (Basel)
Pays: Switzerland
ID NLM: 101530765

Informations de publication

Date de publication:
01 10 2020
Historique:
received: 26 08 2020
revised: 24 09 2020
accepted: 30 09 2020
entrez: 6 10 2020
pubmed: 7 10 2020
medline: 17 6 2021
Statut: epublish

Résumé

Uremic toxins (UTs) generally accumulate in patients developing end-stage renal disease (ESRD). Although some kinds of UTs cause early death after starting hemodialysis (HD), it remains unknown whether the degree of excessive accumulation of various UTs is associated with worsening of prognosis. We retrospectively conducted this cohort study consisting of adult patients developing ESRD who initiated HD at the National Center for Global Health and Medicine from 2010 to 2019. We created a new uremic score, which was defined as the aggregate score of the following variables reflecting uremic state: elevated blood urea nitrogen, β2-microglobulin, and anion gap before starting HD. The primary outcome was early mortality within 1-year after HD commencement. The hazard ratio (HR) and 95% confidence interval (CI) for a one-point increase in uremic score was calculated with Cox proportional hazard models adjusted by baseline conditions. We included 230 participants, 16 of whom experienced the primary outcome of early mortality after HD commencement. Uremic score was significantly associated with the primary outcome (crude HR: 1.91, 95% CI 1.16-3.14; adjusted HR: 4.19, 95% CI 1.79-9.78). Our novel uremic score, reflecting accumulation of specific UTs, more precisely predicts early mortality after HD commencement.

Identifiants

pubmed: 33019590
pii: toxins12100634
doi: 10.3390/toxins12100634
pmc: PMC7601006
pii:
doi:

Substances chimiques

B2M protein, human 0
Biomarkers 0
Toxins, Biological 0
beta 2-Microglobulin 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Clin Exp Nephrol. 2020 Nov;24(11):1077-1083
pubmed: 32748309
Clin J Am Soc Nephrol. 2006 Sep;1(5):915-9
pubmed: 17699307
J Am Soc Nephrol. 2006 Feb;17(2):546-55
pubmed: 16382021
Acta Clin Belg. 2019 Feb;74(1):2-6
pubmed: 29757121
N Engl J Med. 2007 Sep 27;357(13):1316-25
pubmed: 17898101
Clin J Am Soc Nephrol. 2006 Sep;1(5):903-4
pubmed: 17699303
Toxins (Basel). 2018 Jan 08;10(1):
pubmed: 29316724
Sci Transl Med. 2013 Mar 6;5(175):175ra29
pubmed: 23467560
PLoS One. 2016 Jun 01;11(6):e0156381
pubmed: 27249416
N Engl J Med. 1981 Nov 12;305(20):1176-81
pubmed: 7027040
Blood Purif. 2019;48(4):299-314
pubmed: 31563911
Front Med (Lausanne). 2017 Jun 15;4:73
pubmed: 28664159
J Am Soc Nephrol. 1999 Aug;10(8):1815-23
pubmed: 10446951
Clin Exp Nephrol. 2020 May;24(5):458-464
pubmed: 31984460
Ther Apher Dial. 2015 Mar;19 Suppl 1:93-107
pubmed: 25817934
Am J Kidney Dis. 2013 Jul;62(1):42-51
pubmed: 23518194
Lancet Diabetes Endocrinol. 2016 Apr;4(4):360-73
pubmed: 26948372
Ther Apher Dial. 2012 Apr;16(2):111-20
pubmed: 22458388
Clin Chim Acta. 1999 Nov;289(1-2):69-78
pubmed: 10556654
Kidney Int. 2008 Feb;73(4):391-8
pubmed: 18094682
J Am Soc Nephrol. 2014 Oct;25(10):2151-8
pubmed: 24812163
Crit Care Med. 2016 Feb;44(2):e83-8
pubmed: 26465222
Wien Klin Wochenschr. 1998 Aug 21;110(15):511-20
pubmed: 9782569
Am J Kidney Dis. 2009 Jun;53(6):982-92
pubmed: 19339088

Auteurs

Yohei Arai (Y)

Department of Nephrology, National Center for Global Health and Medicine, Tokyo 162-8655, Japan.
Department of Nephrology, Tokyo Medical and Dental University, Tokyo 113-8510, Japan.

Shingo Shioji (S)

Department of Nephrology, Yokosuka Kyosai Hospital, Kanagawa 238-8558, Japan.

Hiroyuki Tanaka (H)

Department of Nephrology, Yokosuka Kyosai Hospital, Kanagawa 238-8558, Japan.

Daisuke Katagiri (D)

Department of Nephrology, National Center for Global Health and Medicine, Tokyo 162-8655, Japan.

Fumihiko Hinoshita (F)

Department of Nephrology, National Center for Global Health and Medicine, Tokyo 162-8655, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH